Research programme: antibody therapeutics - Alder Biopharmaceuticals/Merck & Co

Drug Profile

Research programme: antibody therapeutics - Alder Biopharmaceuticals/Merck & Co

Latest Information Update: 13 Dec 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alder Biopharmaceuticals; Schering-Plough
  • Developer Alder Biopharmaceuticals; Merck & Co
  • Class Antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Unspecified

Most Recent Events

  • 25 Aug 2009 Preclinical development is ongoing in USA
  • 11 Jun 2009 Alder and Schering-Plough expand collaboration to identify and develop therapeutic monoclonal antibodies in the USA
  • 14 Dec 2005 Preclinical trials in Undefined in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top